[{"orgOrder":0,"company":"Galderma","sponsor":"Certara","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara Partners with Galderma in Advancing Modeling and Simulation Technology to Attain FDA Approval of AKLIEF\u00ae Topical Acne Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Codexis and Nestl\u00e9 Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Science","highestDevelopmentStatusID":"2","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Science"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","amount":"$473.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aimmune Announces $200 Million Equity Investment by Nestle","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Collaboration","leadProduct":"Peanut (Arachis hypogaea) Allergen-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0.46999999999999997,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.46999999999999997,"dosageForm":"Oral Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Science","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Science"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Xencor","pharmaFlowCategory":"D","amount":"$395.0 million","upfrontCash":"$10.0 million","newsHeadline":"Aimmune Licenses Worldwide Rights to Xencor\u2019s XmAb\u00ae7195","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"XmAb7195","moa":"IgE","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I","graph3":"Aimmune Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Aimmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aimmune Therapeutics \/ Aimmune Therapeutics"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"D","amount":"$67.1 million","upfrontCash":"$5.1 million","newsHeadline":"VALBIOTIS inks Strategic Partnership With NESTL\u00c9 HEALTH SCIENCE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"TOTUM-63","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0.070000000000000007,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Science"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Results from Phase 2 Study of Investigational Therapy Nemolizumab for Moderate to Severe Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport\u00ae Achieved High Levels of Satisfaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Aimmune Therapeutics","pharmaFlowCategory":"D","amount":"$1,930.0 million","upfrontCash":"$1,930.0 million","newsHeadline":"Nestl\u00e9 to Acquire Aimmune Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Acquisition","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":1.9299999999999999,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":1.9299999999999999,"dosageForm":"Powder","sponsorNew":"Nestle Health Sciences SA \/ Nestl\u00e9","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestl\u00e9"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Receives Positive CHMP Opinion on PALFORZIA\u00ae for the Treatment of Patients with Peanut Allergy in Europe","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"European Commission Approves Aimmune's PALFORZIA\u00ae As First-Ever Treatment for Peanut Allergy in the EU","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Peanut Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder in capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Senda Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Senda Biosciences and Nestl\u00e9 Health Science Enter into an Option Agreement for Senda's Intersystems Biology-Based Metabolic Health Products","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"Nutritional therapies","moa":"","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Nutrition and Weight Loss","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Firmicute species bacterial spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Encapsulated purified suspension","sponsorNew":"Nestle Health Sciences SA \/ Nestle","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestle"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA\u00ae for up to ~3.5 Years","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis hypogaea allergen powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral powder in capsules","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for Restylane\u00ae Defyne for Chin Augmentation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable Gel Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","amount":"$525.0 million","upfrontCash":"$175.0 million","newsHeadline":"Seres Therapeutics, Nestl\u00e9 Health Science Announce SER-109 Co-Commercialization License Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spores","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Oral","sponsorNew":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"10","companyTruncated":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune to Present New Two-Year Treatment Satisfaction Data","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune\u2019s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA\u00ae Safety and Efficacy Increased Over Time in Patients with Peanut Allergy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Presents New Nemolizumab Data at EADV Reinforcing Rapid Onset of Action and Consistent Relief of Symptoms for People With Prurigo Nodularis and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA\u00ae in Clinical Practice in the U.S.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Oral Powder In Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Therapeutics Presents New PALFORZIA\u00ae [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Arachis Hypogaea Allergen Powder-dnfp","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for New SCULPTRA\u00ae Label, Offering More Options to Aesthetic Partners","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"Collagen hydrolysis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galderma Successfully Completes Acquisition of ALASTIN Skincare","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Alastin Skincare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Galderma to Acquire Award-Winning ALASTIN Skincare\u00ae Enhancing its Integrated Dermatology Platform to Continue Delivering the Best Experience to Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2021","year":"2021","type":"Acquisition","leadProduct":"Herbal Extract","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"$99.3 million","upfrontCash":"Undisclosed","newsHeadline":"Sun Pharma's US subsidiary acquires Galderma's companies in US, Japan & Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Acquisition","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.10000000000000001,"dosageForm":"Topical Solution","sponsorNew":"Galderma \/ Taro Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Taro Pharmaceutical"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma to Present New Clinical Data and High Patient Satisfaction Across Their Portfolio of Dermal Fillers, Collagen Biostimulators and Liquid Neuromodulators at AMWC 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Galderma \/ Ipsen","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Ipsen"},{"orgOrder":0,"company":"Galderma","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 Health Science Partners with Bioiberica to Deliver Innovative Nutrition in Joint Health and Mobility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"GALDERMA LABS LP","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Technologies Announces FDA Approval of TWYNEO\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Tretinoin","moa":"RAR","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"GALDERMA LABS LP","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Cream","sponsorNew":"GALDERMA LABS LP \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GALDERMA LABS LP \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma to Present Extensive New Clinical Data Across Its Portfolio of Neuromodulators, Fillers and Biostimulators at the IMCAS World Congress 2022","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"Ach","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Launches EPSOLAY\u00ae Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"Keratinocyte","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Cream","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Positive Results in Two Phase III Studies for a Novel Liquid Formulation Botulinumtoxina (Relabotulinumtoxina) for the Treatment of Glabellar Lines (Frown) and Lateral Canthal Lines (Crow\u2019s Feet)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"Ach","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aimmune Tx to Present New Data for PALFORZIA at the EAACI","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Arachis Hypogaea","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Enterome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$40.7 million","newsHeadline":"Enterome Signs Major Strategic R&D Collaboration with Nestl\u00e9 Health Science to Develop and Commercialize New AllerMimics\u2122 and EndoMimics\u2122 Immunotherapies for Food Allergies and Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Collaboration","leadProduct":"EB1010","moa":"IL-10","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science","highestDevelopmentStatusID":"4","companyTruncated":"Nestle Health Sciences SA \/ Nestl\u00e9 Health Science"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data From Galderma's Aesthetics Portfolio To Be Presented At 2022 ASDS Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"BotulinumtoxinA","moa":"ACh","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Aimmune Therapeutics","sponsor":"Allergy Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Allergy Partners Announces Collaboration with Aimmune Therapeutics to Provide PALFORZIA\u00ae [Peanut (arachis hypogaea) Allergen Powder-dnfp] Directly to Patients","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"Arachis Hypogaea","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Aimmune Therapeutics","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Powder","sponsorNew":"Aimmune Therapeutics \/ Allergy Partners","highestDevelopmentStatusID":"12","companyTruncated":"Aimmune Therapeutics \/ Allergy Partners"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IMCAS 2023: Galderma to Share Latest Data Demonstrating High Aesthetic Improvement and Patient Satisfaction Across Its Innovative Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codexis and Nestl\u00e9 Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AMWC 2023: Data From Sculptra\u00ae Cheek Wrinkle and Alluzience\u00ae Star Studies Reinforce Strength of Galderma\u2019s Broad Aesthetic Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics and Nestl\u00e9 Health Science Announce FDA Approval of Vowst\u2122 (fecal Microbiota Spores, Live-Brpk) for Prevention of Recurrence of C. Difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Valbiotis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II\/III Clinical Study on TOTUM\u202263: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"TOTUM\u202263","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","amount":"$525 million","upfrontCash":"$175 million","newsHeadline":"Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestl\u00e9 Health Science Following FDA Approval of VOWST\u2122","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Agreement","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0.53000000000000003,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Seres Therapeutics and Nestl\u00e9 Health Science Announce U.S. Commercial Availability of VOWST\u2122, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fecal Microbiota Spores Live-brpk","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$41.1 million","upfrontCash":"$13.7 million","newsHeadline":"Ipsen Ends Neurotoxin Pact with Galderma after Arbitration Cases Filed in International Court","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Termination","leadProduct":"Botulinum toxin type A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Galderma","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"7","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Galderma","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Updates on Nemolizumab Development","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Galderma","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Galderma"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Codexis","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"$5.0 million","newsHeadline":"Codexis Announces Purchase Agreement with Nestl\u00e9 Health Science for CDX-7108","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Agreement","leadProduct":"CDX-7108","moa":"","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0.050000000000000003,"therapeuticAreaNew":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Codexis","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Codexis"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TOXINS 2024: Galderma\u2019s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow\u2019s Feet Simultaneously","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results From Galderma\u2019s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow\u2019s Feet and Frown Lines","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 Agrees to Acquire Global Rights to VOWST\u00ae, Product it Launched in June 2023","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Fecal Microbiota Spores Live","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"12","companyTruncated":"Nestle Health Sciences SA \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma\u2019s Relfydess\u2122 (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"RelabotulinumtoxinA","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Receives FDA Approval for Nemluvio\u00ae in Adults with Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2024","year":"2024","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"","highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"13","companyTruncated":"Galderma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Nestle Health Sciences SA
Details :
Nemluvio (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, approved for the treatment of patients with prurigo nodularis.
Details :
Relfydess (relabotulinumtoxinA) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology for moderate to severe vertical frown lines.
Details :
Nestlé will acquire certain assets associated with VOWST (fecal microbiota spores), the first and only FDA approved oral therapeutic to prevent recurrence of Clostridioides difficile infection.
Details :
CD14152 (nemolizumab) is a humanized anti-human IL-31 receptor A monoclonal antibody, which is being evaluated for the treatment of patients with prurigo nodularis & for adolescents and adults with moderate to severe atopic dermatitis.
Details :
QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.
Details :
Through agreement, Nestlé Health Science will be solely responsible for the continued development and commercialization of CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency (EPI).
Details :
QM1114-DP (RelabotulinumtoxinA) is a rapid and long lasting small molecule injection formulation, which is being investigated for dermatological conditions like Crow’s Feet and Frown Lines.
Details :
Under the termination, Ipsen will retain all rights and obligations related to its early-stage R&D neurotoxin pipeline, including the development of IPN10200 (abobotulinumtoxinA), for the treatment of upper facial lines and muscle spasticity.
Details :
Vowst (fecal microbiota spores, live-brpk) is approved by FDA as the first orally administered microbiota-based therapeutic for the prevention of recurrent C. difficile infection (CDI).
Brand Name : Vowst
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 05, 2023
Lead Product(s) :
Fecal Microbiota Spores Live-brpk
Details :
The agreement aimed to jointly commercialize Vowst (fecal microbiota spores, live-brpk), an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection in adults following antibiotic treatment for recurrent CDI, follo...
Brand Name : Vowst
Molecule Type : Large molecule
Upfront Cash : $175 million
May 30, 2023
Lead Product(s) :
Fecal Microbiota Spores Live-brpk